Broad therapeutic benefit of myosin inhibition in hypertrophic cardiomyopathy
L. Sen Martin, A. Fernandez Trasancos, M. A. Lopez Unzu, D. Pathak, A. Ferrarini, V. Labrador Cantarero, D. Sanchez Ortiz, M. R. Pricolo, N. Vicente, D. Velazquez Carreras, L. Sanchez Garcia, J. A. Nicolas Avila, M. Sanchez Diaz, S. Schlossarek, L. Cusso, , J. Alegre Cebollada
This study shows that myosin inhibition with mavacamten is effective in treating HCM caused by both truncating and missense variants in MYBPC3, despite different pathomechanisms.
bioRxiv · Mar 22, 2024Physiology